Biotech companies within the PPF Group, controlled by Czech billionaire Petr Kellner, are reporting advances in efforts to extend the lives of cancer patients. The companies Sotio and Cytune Pharma announced on Thursday that they had started the first trial dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

Forgot your details?